I'm LongbridgeAI, I can summarize articles.Analyst Serge Belanger from Needham has reiterated a Buy rating on Trevi Therapeutics, lowering the price target to $23. The decision is based on the company's advancing clinical pipeline, including four late-stage studies of Haduvio set for 2026. Initial efficacy data is expected in 2027. Belanger notes Trevi's solid financial position, with approximately $334 million in cash to support operations until 2030. He has an average return of 13.4% and a 50.60% success rate on recommended stocks.
Trevi Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $23.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Serge Belanger has given his Buy rating due to a combination of factors that underscore Trevi Therapeutics’ advancing clinical pipeline and solid financial footing. The company is launching four late-stage studies of Haduvio across several refractory cough settings in 2026, with initial efficacy data expected to start reading out in the second half of 2027, which could provide multiple value‑creating catalysts.
In the nearer term, investor attention is likely to focus on external validation from a Phase 3 readout of GSK’s camlipixant in refractory chronic cough and Trevi’s own Phase 2b RCC trial analyses later in 2026, events that may help frame expectations for Haduvio’s potential. Belanger maintains a Buy rating while modestly trimming the price target to $23 to reflect minor modeling changes, emphasizing that Trevi’s approximate $334 million in pro‑forma cash should fund operations into 2030 and support execution of its development and commercial plans.
Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Esperion, and Trevi Therapeutics. According to TipRanks, Belanger has an average return of 13.4% and a 50.60% success rate on recommended stocks.